Vendor Intelligence Report: Wolverine Peptides

Executive summary

Across 1 Finnrick lab test, Wolverine Peptides has 0 pass / 1 fail — an overall pass rate of 0%. The current Finnrick file covers only Retatrutide, and that one sample failed; the sample size is too small for a catalogue-wide verdict, but it is enough to make Wolverine a weak Retatrutide choice without a fresh batch-matched independent COA. The report also shows the rating is highly sensitive to stricter grading.

Outside the lab record, Wolverine is a traceable but unevenly disclosed UK storefront. The site shows a polished research brand with Klarna, discreet shipping, testimonials, Janoshik COAs, and franchise messaging, but it does not display the registered company name or number on the captured public pages. The full attribution runs through Companies House records, a shared-hosting lead with an Uddin-linked site, and a Cheshire Digital case study describing Wolverine as a new brand built from scratch.

Wolverine’s buyer-positive evidence is its vendor-published Janoshik page: eight named-batch COAs, including BPC-157, TB-500, MOTS-C and SS-31, appear visually genuine. The limits are just as important: the reports cover only part of the catalogue, use an Anonymous client name, could not be portal-verified during the run, and do not include sterility, endotoxin, particulate, manufacturer, or GMP-certificate evidence.

The sharpest non-lab risk is consumer-use signaling. Oral BPC-157 tablets showing 1,773 units sold, named stacks, affiliate discount codes aimed at fitness users, Telegram promotion, discreet-shipping language, and a visible franchise pitch all weaken the research-use posture. The report also separates the assessed .co.uk domain from unresolved .net referral promotion because channel confusion can decide which entity, COA, and support route stand behind a vial.

Inside the full report:

• Appendix A — Finnrick Laboratory Data and methodology-divergence charts for the Retatrutide result
• Companies House and officer-record attribution for the legal entity behind the trading name
• Shared-IP and Cheshire Digital developer-ecosystem analysis, including comparison vendors
• Janoshik COA review with batch keys, anonymous-client limitations, and missing sterility/endotoxin evidence
• Affiliate and channel-control map covering .co.uk, .net referral links, Telegram, Reddit, and coupon surfaces
• Regulatory-risk review of BPC-157 tablets, named stacks, franchise marketing, and MHRA context

Risk assessment

• Human-use marketing and MHRA enforcement concern — high: BPC-157 Tablets, named stacks, Klarna/discreet-shipping signals, and human-outcome promotion conflict with a strict research-use posture.
• Affiliate-promotion and disclosure concern — high: Personal codes/referral links and fitness-outcome promotion were documented with no clear disclosure on most referral-carrying promoters.
• Brand-confusion and unofficial-channel concern — medium: The assessed official domain is wolverinepeptides.co.uk, while promotions surfaced wolverinepeptides.net and unverified social channels without an authoritative reseller/channel list.
• Retatrutide quality concern — medium: Finnrick has one Retatrutide test for Wolverine Peptides, with 0 pass / 1 fail and a current rating of 76.43%; sample size is small but currently unfavorable.
• Injectable batch-verification and sterility evidence gap — medium: Published Janoshik COAs cover only a subset and address chemical purity, not sterility, endotoxin, particulate load, GMP certification, or current-shipping batch match.
• Corporate accountability concern — medium: The site omits registered company name/number; WOLVERINE RESEARCH UK LTD was identified by investigation, is young, and uses a residential registered office.